<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751803</url>
  </required_header>
  <id_info>
    <org_study_id>1246.4</org_study_id>
    <secondary_id>EudraCT No : 2008-000079-31</secondary_id>
    <nct_id>NCT00751803</nct_id>
  </id_info>
  <brief_title>BI 44370 TA in Acute Migraine Attack</brief_title>
  <official_title>A Randomised, Double-blind, Placebo- and Active Comparator-controlled, Five Parallel Groups Study to Investigate the Efficacy and Safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe Intensity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this trial is to assess the safety, tolerability, and efficacy of three
      doses of BI 44370 TA in the treatment of patients with an acute migraine attack and headache
      pain of moderate or severe intensity, compared to placebo and an active comparator.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is a pain free response, defined as reduction of severe or moderate headache to no headache, 2 hours after dosing.</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain-free response 0.5, 1, 1.5, 24 and 48 hours after dosing</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief, defined as reduction of severe or moderate headache to mild or no headache, 0.5, 1, 1.5, 2, 24 and 48 hours after dosing</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained pain-free response, defined as reduction of severe or moderate headache to no headache 2 hours after dosing and remaining pain-free up to 24 and 48 hours after dosing</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained pain relief response, defined as reduction of severe or moderate headache to mild or no headache 2 hours after dosing and no worsening up to 24 and 48 hours after dosing</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of headache at the time of intake of study medication, and 0.5, 1, 1.5, 2, 24 and 48 hours after dosing</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief of associated migraine symptoms (nausea, vomiting, photophobia, phonophobia) 0.5, 1, 1.5, 2, 24 and 48 hours after dosing</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to meaningful relief, defined by the patient as occurring when relief of pain and associated symptoms becomes meaningful, up to 2 h after dosing</measure>
    <time_frame>up to 2 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of medication by the patient evaluated 48 h after study drug intake</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional disability assessed by the patient measured at the time of intake of study medication, and 0.5, 1, 1.5, 2, 24 and 48 hours post dosing</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to and use of rescue medication within 24 and 48 hours</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence / relapse of headache during time-intervals of 2-24 and 2-48 hours post dosing</measure>
    <time_frame>up to 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of adverse events</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in safety laboratory parameters</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in vital sign parameters</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawals due to adverse events</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">416</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>BI 44370 TA Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 44370 TA Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 44370 TA High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eletriptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 44370 TA Low Dose</intervention_name>
    <arm_group_label>BI 44370 TA Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eletriptan</intervention_name>
    <arm_group_label>Eletriptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>BI 44370 TA Low Dose</arm_group_label>
    <arm_group_label>BI 44370 TA Medium Dose</arm_group_label>
    <arm_group_label>BI 44370 TA High Dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Eletriptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 44370 TA Medium Dose</intervention_name>
    <arm_group_label>BI 44370 TA Medium Dose</arm_group_label>
    <arm_group_label>BI 44370 TA High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult migraine patients with or without aura, diagnosed according to the ICH.

          -  Established migraine diagnosis greater than or equal to 1 year.

          -  Age at first migraine onset latest at 50 years of age.

          -  Medical history of migraine with headache of moderate to severe intensity and migraine
             frequency of 2-8 times/ month.

          -  Patient has provided written informed consent in accordance with ICH-GCP and local
             legislation.

        Exclusion Criteria:

          -  History of hemiplegic, ophthalmoplegic or basilar migraine, or cluster headache.

          -  History of treatment-resistant migraine attacks.

          -  Other pain syndromes possibly interfering with study assessment or use of any pain
             medication &gt; 10 days / month.

          -  Use of migraine and other restricted medication, or other restrictions as per
             protocol.

          -  Pregnancy or breast-feeding. Female of childbearing potential who do not use
             contraception.

          -  Clinically significant cardiovascular, peripheral vascular, hepatic, respiratory,
             haematological, gastrointestinal, renal, metabolic, immunological, hormonal,
             neurological and psychiatric disorders.

          -  Patients in whom unrecognised coronary artery disease is likely, or who are at risk of
             coronary artery disease indicated by the presence of risk factors.

          -  Persistent liver enzyme elevation such as ALT, AST or AP &gt; 2x ULN.

          -  Known history of HIV, or history of cancer within the last 5 years.

          -  DSM-IV-defined-history of substance abuse or dependence within the past 6 months,
             excluding nicotine and caffeine, but including alcohol or benzodiazepines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1246.4.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.32009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.32007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montegnee</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3307B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3304B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erkelenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goettingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grevenbroich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huettenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koenigstein im Taurus</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blaricum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vallingby</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.44013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1246.4.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Whitechapel, London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>El Salvador</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2014</disposition_first_posted>
  <last_update_submitted>November 12, 2014</last_update_submitted>
  <last_update_submitted_qc>November 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eletriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

